Deuremidevir
Deuremidevir, also known as VV116, is an nucleoside analogue antiviral drug. It is administrated through oral tablets, which contain the hydrobromide salt of this drug.[1]
![]() | |
Clinical data | |
---|---|
Trade names | 民得维 |
Routes of administration | oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H30DN5O7 |
Molar mass | 502.546 g·mol−1 |
3D model (JSmol) | |
| |
|
Chemically speaking, the drug is a deuterated tri-isobutyrate of GS-441524, the active metabolite of remdesivir. It was first described in an 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.[2] It completed a phase 3 trial in 2022.[3] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.[4]
References
- Zhu, Ke-Wei (8 September 2023). "Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134.
- Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (January 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv. doi:10.1101/2020.11.01.363812. S2CID 226263471.
- Cao, Zhujun; Gao, Weiyi; Bao, Hong; Feng, Haiyan; Mei, Shuya; Chen, Peizhan; Gao, Yueqiu; Cui, Zhilei; Zhang, Qin; Meng, Xianmin; Gui, Honglian; Wang, Weijing; Jiang, Yimei; Song, Zijia; Shi, Yiqing; Sun, Jing; Zhang, Yifei; Xie, Qing; Xu, Yiping; Ning, Guang; Gao, Yuan; Zhao, Ren (28 December 2022). "VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19". New England Journal of Medicine: NEJMoa2208822. doi:10.1056/NEJMoa2208822. PMC 9812289. PMID 36577095.
- Devarasetti, Hasini (2023-01-30). "China's NMPA conditionally approves two oral drugs for Covid-19". Pharmaceutical Technology. Retrieved 2023-02-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.